HC Wainwright & Co. Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $105

HC Wainwright & Co. analyst Raghuram Selvaraju has maintained a 'Buy' rating on Rhythm Pharmaceuticals (NASDAQ: RYTM) and increased the price target from $100 to $105.